Today (5/18) Moderna announced that its clinical trial in the United States has started to see protective antibodies in data from 8 healthy individuals, chosen at random from a 45-person study. The study, which began in March, and found that the antibodies produced in these individuals is far higher than those who recovered from the COVID-19 infection. While it’s unknown if these results will carry through in the real world, the small success gives hope for the COVID-19 vaccine development. 

Read more here

More on: